Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Iovance Biotherapeutics Inc’s stock clocked out at $6.19, down -0.96% from its previous closing price of $6.25. In other words, the price has decreased by -$0.96 from its previous closing price. On the day, 5.74 million shares were traded. IOVA stock price reached its highest trading level at $6.3 during the session, while it also had its lowest trading level at $6.075.
Ratios:
To gain a deeper understanding of IOVA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.90 and its Current Ratio is at 4.22. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Buy rating and assigned the stock a target price of $17.
On July 29, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $19 to $10.
On November 20, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $12.Goldman initiated its Buy rating on November 20, 2023, with a $12 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 12 ’24 when Maynard Ryan D sold 50,000 shares for $10.06 per share. The transaction valued at 503,000 led to the insider holds 7,500 shares of the business.
Maynard Ryan D bought 50,000 shares of IOVA for $503,104 on Nov 12 ’24. On Feb 20 ’24, another insider, MCPEAK MERRILL A, who serves as the Director of the company, bought 250,000 shares for $9.15 each. As a result, the insider paid 2,287,500 and bolstered with 320,150 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 1886594304 and an Enterprise Value of 1568048128. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.76 while its Price-to-Book (P/B) ratio in mrq is 2.44. Its current Enterprise Value per Revenue stands at 17.258 whereas that against EBITDA is -3.84.
Stock Price History:
The Beta on a monthly basis for IOVA is 0.54, which has changed by -0.19922382 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $18.33, while it has fallen to a 52-week low of $5.57. The 50-Day Moving Average of the stock is -19.03%, while the 200-Day Moving Average is calculated to be -34.03%.
Shares Statistics:
It appears that IOVA traded 7.87M shares on average per day over the past three months and 8832010 shares per day over the past ten days. A total of 304.62M shares are outstanding, with a floating share count of 247.03M. Insiders hold about 18.95% of the company’s shares, while institutions hold 69.13% stake in the company. Shares short for IOVA as of 1736899200 were 61984016 with a Short Ratio of 7.88, compared to 1734048000 on 59327307. Therefore, it implies a Short% of Shares Outstanding of 61984016 and a Short% of Float of 22.479999.
